Related Experiment Video
Updated: Oct 11, 2025
06:39
Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
Published on: June 13, 2025
164
Low-Molecular-Weight Heparin Prophylaxis Dosing: Is Weight an Issue?
Molly G Minze1, Yu-Yu Kwee2, Ronald G Hall2
1Texas Tech University Health Sciences Center, Abilene, TX, USA.
Summary
Dosing low-molecular-weight heparins (LMWHs) for venous thromboembolic event (VTE) prophylaxis in obese patients requires further study. Current data suggest increased enoxaparin doses may be effective, but optimal adjustments remain unclear.
Area of Science:
- Pharmacology
- Thrombosis
- Obesity Medicine
Background:
- Obesity presents unique challenges in VTE prophylaxis.
- Standard dosing of low-molecular-weight heparins (LMWHs) may be suboptimal in obese individuals.
- Limited data exist on optimal LMWH dosing for VTE prevention in this population.
Purpose of the Study:
- To review pharmacokinetic, safety, and effectiveness data of LMWH dosing for VTE prophylaxis in obese patients.
- To identify gaps in current knowledge regarding LMWH use in obesity.
- To provide recommendations for LMWH dosing in obese individuals.
Main Methods:
- Systematic literature search of PubMed (1966-2015) using keywords: low-molecular-weight heparin, prophylaxis, obesity.
- Inclusion of pharmacokinetic studies, clinical trials, and retrospective evaluations.
- Analysis of anti-Xa levels, safety, and effectiveness data related to weight and obesity.
Main Results:
- Most data focus on enoxaparin, supporting increased dosing in obese patients, though optimal adjustment is uncertain.
- Recommended enoxaparin dose: 40 mg twice daily based on available effectiveness data.
- Dalteparin dosing requires no adjustment for class I-II obesity; data for class III obesity are needed.
- Tinzaparin weight-based dosing needs further safety and effectiveness data before routine use.
Conclusions:
- Current data on LMWH dosing for VTE prophylaxis in obese adults are limited.
- High-quality studies are essential to optimize LMWH dosing strategies for obese patients.
- Further research is needed to establish evidence-based guidelines for LMWH use in this demographic.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.0K
01:21Drug Dosing: Obese Patients
13
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
13
01:29Venous Thrombosis III: Interprofessional Care
55
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
55
01:16Insulin: Dosing Regimen and Adverse Effects
300
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
300
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
17
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
17
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
20
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
20